UCB has announced a new collaboration with the University of Oxford that will see the two organisations researching innovative pharmaceuticals.
Under the terms of the new partnership, scientists from the industry and academia will combine resources and expertise to create new immunology and neurology treatments, funded by a UCB contribution of 3.6 billion pounds.
Between five and ten research projects will be carried out over the course of the three-year alliance, with a steering committee of UCB and Oxford University representatives overseeing the collaboration.
This will support recent UK government efforts to foster closer partnerships between different parts of the life science sector.
Roch Doliveux, chief executive of UCB and chairman of the Innovative Medicines Initiative (IMI), said the agreement brings "two parties committed to scientific exploration and the exchange of cutting-edge ideas together on a mission to discover new medicines that will aim to transform the lives of people living with severe diseases".
Mr Doliveux was chosen as chairman of the IMI earlier this month and will be working with the organisation to help foster public-private partnerships across Europe.